Skip to Content

Answers (1)

Official Answer by 30 Nov 2016

Amgen’s Amjevita (adalimumab-atto) is the first adalimumab (Humira) biosimilar approved by the FDA and, like Humira, is used in adults for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis; it is also approved for juvenile idiopathic arthritis (JIA) in children 4 years and older.

Amjevita is not yet approved to treat hidradenitis suppurativa, or uveitis, like Humira. Also, Amjevita is not approved as an interchangeable product at the pharmacy, meaning the pharmacist needs approval from the prescribing doctor to substitute Amjevita for Humira if not specified on the prescription.

Like Humira, Amjevita is an anti-TNF-α monoclonal antibody that has the same amino acid sequence as adalimumab.

Common side effects include infections and injection site reactions.

Amjevita is available in a prefilled syringe or autoinjector and is given by a subcutaneous injection.

See also:

Votes: +0 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What is the difference between Biktarvy and Descovy?

Posted 16 days ago 1 answerFAQ by

What is the difference between Symdeko and Orkambi?

Posted 16 days ago 1 answerFAQ by